69例年轻乳腺癌新辅助化疗的疗效和影响因素分析

An Analysis of Influence Factors on Neoadjuvant Chemotherapy Efficacy in 69 Young Women with Breast Cancer

[目的]探讨年轻局部晚期乳腺癌的临床病理特点、新辅助治疗的疗效和影响疗效的相关因素。[方法]回顾性分析中国医学科学院肿瘤医院2005年1月至2009年1月收治的年龄小于40岁的接受术前化疗的局部晚期乳腺癌患者资料。[结果]全组患者病理完全缓解9例(13.0%),有效率76.8%(53/69);1例病情进展。5例在化疗后接受了保乳手术。单因素分析发现,含紫杉类方案(TE)是影响新辅助化疗疗效因素(P<0.05),而组织学分级,肿瘤大小,淋巴结状况,ER、PR、HER-2表达和分子分型与新辅助化疗疗效无关。[结论]年轻局部晚期乳腺癌对术前化疗敏感,含紫杉类药物的方案有助于提高化疗疗效。

[Purpose] To investigate the clinical characteristics,treatment and prognostic factors of neoadjuvant chemotherapy（NAC） in young patients with locally advanced breast cancer.[Methods] The clinical data of 69 patients histologically diagnosed with locally advanced breast cancer at the age of ≤40 in Hospital of Chinese Academy of Medical Science and treated with NAC and surgery from January 2003 to January 2010 were analyzed retrospectively.[Results] Pathologic complete response（pCR） was achieved in 13.0%（9/63）,and the overall response was 76.8%（53/69）;1 patient had progress disease.Five patients received breast conservative surgery after NAC.Univariate analysis showed that TE regimen was an independent factor which influenced NAC efficacy（P0.05）,but the histological grade,lymph node status,estrogen receptor,progesterone receptor,human epidermal growth factor receptor 2 were not correlated to NAC efficacy.[Conclusion] Young patients with locally advanced breast cancer are chemosensitive to NAC.The regimen with anthracycline and taxane is helpful to improve NAC efficacy.